179 related articles for article (PubMed ID: 36889811)
1. Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression.
Bruni S; Mauro FL; Proietti CJ; Cordo-Russo RI; Rivas MA; Inurrigarro G; Dupont A; Rocha D; Fernández EA; Deza EG; Lopez Della Vecchia D; Barchuk S; Figurelli S; Lasso D; Friedrich AD; Santilli MC; Regge MV; Lebersztein G; Levit C; Anfuso F; Castiglione T; Elizalde PV; Mercogliano MF; Schillaci R
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36889811
[TBL] [Abstract][Full Text] [Related]
2. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
3. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
Mercogliano MF; Inurrigarro G; De Martino M; Venturutti L; Rivas MA; Cordo-Russo R; Proietti CJ; Fernández EA; Frahm I; Barchuk S; Allemand DH; Figurelli S; Deza EG; Ares S; Gercovich FG; Cortese E; Amasino M; Guzmán P; Roa JC; Elizalde PV; Schillaci R
BMC Cancer; 2017 Dec; 17(1):895. PubMed ID: 29281999
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
Chen AC; Migliaccio I; Rimawi M; Lopez-Tarruella S; Creighton CJ; Massarweh S; Huang C; Wang YC; Batra SK; Gutierrez MC; Osborne CK; Schiff R
Breast Cancer Res Treat; 2012 Jul; 134(2):583-93. PubMed ID: 22644656
[TBL] [Abstract][Full Text] [Related]
5. Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.
Wimana Z; Gebhart G; Guiot T; Vanderlinden B; Morandini R; Doumont G; Sherer F; Van Simaeys G; Goldman S; Ghanem G; Flamen P
Mol Imaging Biol; 2015 Oct; 17(5):697-703. PubMed ID: 25761907
[TBL] [Abstract][Full Text] [Related]
6. The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer.
Hu X; Liu Y; Zhang X; Kong D; Kong J; Zhao D; Guo Y; Sun L; Chu L; Liu S; Hou X; Ren F; Zhao Y; Lu C; Zhai D; Yuan X
Neoplasia; 2020 Nov; 22(11):539-553. PubMed ID: 32966956
[TBL] [Abstract][Full Text] [Related]
7. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking.
Li L; Liu T; Shi L; Zhang X; Guo X; Hu B; Yao M; Zhu H; Yang Z; Jia B; Wang F
Theranostics; 2022; 12(12):5551-5563. PubMed ID: 35910795
[No Abstract] [Full Text] [Related]
8. Catecholamine-Induced β2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression.
Shi M; Yang Z; Hu M; Liu D; Hu Y; Qian L; Zhang W; Chen H; Guo L; Yu M; Song L; Ma Y; Guo N
J Immunol; 2013 Jun; 190(11):5600-8. PubMed ID: 23630346
[TBL] [Abstract][Full Text] [Related]
9. Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer.
Bloom MJ; Jarrett AM; Triplett TA; Syed AK; Davis T; Yankeelov TE; Sorace AG
BMC Cancer; 2020 Apr; 20(1):359. PubMed ID: 32345237
[TBL] [Abstract][Full Text] [Related]
10. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression.
Li G; Zhao L; Li W; Fan K; Qian W; Hou S; Wang H; Dai J; Wei H; Guo Y
Oncotarget; 2014 Sep; 5(18):8317-29. PubMed ID: 25327561
[TBL] [Abstract][Full Text] [Related]
11. A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM).
Wege AK; Kirchhammer N; Kazandjian LV; Prassl S; Brandt M; Piendl G; Ortmann O; Fischer S; Brockhoff G
J Transl Med; 2020 Aug; 18(1):316. PubMed ID: 32799890
[TBL] [Abstract][Full Text] [Related]
12. N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by
Wimana Z; Gebhart G; Guiot T; Vanderlinden B; Larsimont D; Doumont G; Van Simaeys G; Goldman S; Flamen P; Ghanem G
Oncotarget; 2017 Aug; 8(34):56185-56198. PubMed ID: 28915583
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
Oshima Y; Tanaka H; Murakami H; Ito Y; Furuya T; Kondo E; Kodera Y; Nakanishi H
Gastric Cancer; 2014; 17(3):450-62. PubMed ID: 23948998
[TBL] [Abstract][Full Text] [Related]
14. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
Li Y; Chu J; Feng W; Yang M; Zhang Y; Zhang Y; Qin Y; Xu J; Li J; Vasilatos SN; Fu Z; Huang Y; Yin Y
FASEB J; 2019 Apr; 33(4):4851-4865. PubMed ID: 30620624
[TBL] [Abstract][Full Text] [Related]
15. Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation.
Shi Y; Fan X; Meng W; Deng H; Zhang N; An Z
Breast Cancer Res; 2014 Apr; 16(2):R33. PubMed ID: 24693969
[TBL] [Abstract][Full Text] [Related]
16. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
17. A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo.
Shu M; Yan H; Xu C; Wu Y; Chi Z; Nian W; He Z; Xiao J; Wei H; Zhou Q; Zhou JX
Sci Rep; 2020 Feb; 10(1):2986. PubMed ID: 32076029
[TBL] [Abstract][Full Text] [Related]
18. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
19. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated macrophages (TAMs) modulate response to HER2-targeted agents in a humanized mouse model of breast cancer.
Loi M; Salvatore G; Sottili M; Calosi L; Desideri I; Becherini C; Salvestrini V; Ciccone LP; Stocchi G; Meattini I; Francolini G; Mangoni M; Livi L
Clin Transl Oncol; 2022 Jul; 24(7):1395-1402. PubMed ID: 35212924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
